TrialJournal of the National Cancer Institute2024

Combining antivascular endothelial growth factor and anti-epidermal growth factor receptor antibodies: randomized phase II study of irinotecan and cetuximab with/without ramucirumab in second-line colorectal cancer (ECOG-ACRIN E7208).

Howard S Hochster et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.